- Ritter Pharmaceuticals - http://www.ritterpharmaceuticals.com -

Press Releases / News

Press Releases / News

2018

August – Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Progress [1]

June – Ritter Pharmaceuticals Initiates First Pivotal Phase 3 Trial for RP-G28 for the Treatment of Lactose Intolerance [2]

June – Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer [3]

June – Ritter Pharmaceuticals Highlights Key Phase 2b Clinical Trial Data of RP-G28 for Lactose Intolerance at Digestive Disease Week 2018 [4]

May – Ritter Pharmaceuticals Announces Appointment of John W. Beck as Chief Financial Officer [5]

May – Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose Intolerance [6]

May – Ritter Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Updates [7]

May – Ritter Pharmaceuticals Selects Medpace as its Clinical Research Organization for Pivotal Phase 3 Clinical Trial of RP-G28 in Lactose Intolerance [8]

March – Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock Split [9]

March – Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update [10]

March – Ritter Pharmaceuticals Reports Microbiome Data from Phase 2b Study of RP-G28 Promotes Beneficial Adaptation of the Gut Microbiome [11]

March – Ritter Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13 [12]

March – Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split [13]

February – Ritter Pharmaceuticals Appoints Distinguished Gastroenterologist, William Chey, M.D., to Medical Advisory Board [14]

January – Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical Trial [15]

2017

November – Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017 [16]

November – Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress [17]

October – Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update [18]

October – Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance [19]

September – Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering [20]

August – Ritter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance [21]

August – Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update [22]

August – Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms [23]

May – Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Updates [24]

May – Ritter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-G28, and Provides an Update on its Path Forward into Phase 3 [25]

April – Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities [26]

March – Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial [27]

February – Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update [28]

February – Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy [29]

January – Ritter Pharmaceuticals to Ring Today’s Nasdaq Stock Market Closing Bell to Kick-off Lactose Intolerance Awareness Month [30]

January – Ritter Pharmaceuticals Announces Collaboration with University of Nebraska to Explore Development of Microbiome Therapeutics in Metabolic Syndrome [31]

January – Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors [32]

January – Ritter Pharmaceuticals Phase 2a Lactose Intolerance Clinical Trial Microbiome Data, Published in Proceedings of the National Academy of Sciences [33]

2016

November – CNBC Article by Andrew Ritter: A Race to Turn Trillions of Our Own Bacteria into Medical Breakthroughs [34]

November – Ritter Pharmaceuticals, Inc. to Present at the 9th Annual LD Micro Main Event on December 7, 2016 [35]

November – Ritter Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results and Provides Business Update [36]

October – Ritter Pharmaceuticals, Inc. Prices $5,000,000 Public Offering of Common Stock [37]

October – Ritter Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock [38]

October – Ritter Pharmaceuticals Concludes Last Patient Visit of its Phase 2b/3 Clinical Trial of RP-G28 for the Treatment of Lactose Intolerance [39]

October – Ritter Pharmaceuticals Presents at the 4th Microbiome R&D Business Collaboration Forum [40]

August – Ritter Pharmaceuticals Completes Enrollment for Phase 2b/3 Trial of RP-G28 in  Lactose Intolerance [41]

August – Ritter Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update [42]

June – Ritter Pharmaceuticals Issued Method of Use Patent for RP-G28 [43]

March – Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update [44]

March – Ritter Pharmaceuticals Doses First Patient in Phase 2b/3 Trial of RP-G28 in Lactose Intolerance [45]

March – Ritter Pharmaceuticals Initiates Phase 2B/3 Clinical Trial of RP-G28 in Lactose Intolerance [46]

March – Ritter Pharmaceuticals to Present at the 28th Annual ROTH Conference [47]

March – Ritter Pharmaceuticals, Inc. Featured in PharmaVOICE [48]

February – Ritter Pharmaceuticals Issued Two New Patents [49]

 

2015

December – Ritter Pharmaceuticals Enters Into a $10 Million Common
Stock Purchase Agreement with Aspire Capital Fund

November – Ritter Pharmaceuticals Provides Third Quarter 2015 Financial Results and Business Update [50]

October – Ritter Pharmaceuticals Appoints William J. Sandborn, M.D. to Medical Advisory Board [51]

October – Ritter Pharmaceuticals Appoints AnnKatrin Petersen-Jappelli, M.D., M.SC. as Chief Medical Officer [52]

October – Ritter Pharmaceuticals to Present at the 2015 Aegis Growth Conference [53]

September – Ritter Pharmaceuticals to Present at the 3rd Microbiome R&D Business Collaboration Forum [54]

August – Ritter Pharmaceuticals Retains William M. Merino as Senior Clinical and Regulatory Advisor [55]

June – Ritter Pharmaceuticals, Inc. Announces Closing of $20,000,000 Initial Public Offering [56]

April – Ritter Pharmaceuticals Names Gastroenterology Industry Veteran Gerald T. Proehl to its Board of Directors [57]

April – Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors [58]

February – Ritter Pharmaceuticals Names Matthew W. Foehr to its Board of Directors [59]

 

2014

September – Ritter Pharmaceuticals Names Michael D. Step Chief Executive Officer [60]

May – Andrew Ritter Named Finalist for 2nd Consecutive Year in LA Business Journal’s Annual Healthcare Leadership Awards [61]

January – Ritter Pharmaceuticals Announces Publication of Lactose Intolerance Phase 2 Trial in Nutrition Journal [62]

 

2013

October – Using Galacto-Oligosaccharides to Improve Lactose Tolerance: Food Technology [63]

June – Ritter Pharmaceuticals’ Study Shows That Altering the Intestinal Microbiome May Offer an Effective Treatment for Lactose Intolerance [64]

April – Andrew Ritter Named Finalist in LA Business Journal’s Annual Healthcare Leadership Awards [65]

April – Patient Survey: More than 80% Forced to Change Lifestyles Due to Lactose Intolerance [66]

March – Ritter Pharmaceuticals Encouraged by Meeting with FDA [67]

February – Ritter Pharmaceuticals Names Larry Good, M.D. Chief Medical Officer [68]

January – Survey: 75% of People with Lactose Intolerance Avoid Dairy Food [69]

January – Lactose Intolerance: Major Unmet Medical Need [70]

 

2012

July – Ritter Pharmaceuticals Appoints Michael Step to the Board of Directors [71]

May – Ritter Pharmaceuticals Presents Its Phase 2 Study of RP-G28 at Digestive Disease Week 2012 [72]

February – Ritter Pharmaceuticals’ Abstract on RP-G28’s Phase 2 Trial Selected for Oral Presentation at Digestive Disease Week 2012 [73]

January – Ritter Pharmaceuticals’ RP-G28 Improves Lactose Intolerance Symptoms and Lactose Digestion in Phase 2 Trial [74]

 

2011

December – Ritter Pharmaceuticals Appoints Robert H. Tidwell as Chief Business Officer [75]

November – Ritter Pharmaceuticals Completes Phase 2 Trial for Lactose Intolerance [76]

June – Ritter Pharmaceuticals, Inc. Announces First Patient Enrollment in its Phase 2 Clinical Study of RP-G28 for the Treatment of Lactose Intolerance [77]

 

2010

November – Ritter Pharmaceuticals, Inc. Awarded a Grant under the U.S. Qualified Therapeutic Discovery Project Program [78]

October – Ritter Pharmaceuticals, Inc. Wins Top Awards at Venture Capital Investment Competition [79]

October – Ritter Pharmaceuticals Wins 2010 San Diego Quick Pitch Competition [80]

June – Ritter Pharmaceuticals, Inc. Receives FDA IND Approval For Lactose Intolerance Treatment [81]

February – Ritter Pharmaceuticals, Inc. to Discuss Lactose Intolerance and Associated Health Risks at NIH Conference [82]

 

2009

September – Ritter Pharmaceuticals’ CEO, Andrew Ritter to Present at the 11th Annual SoCalBio Investor Conference [83]

September – Ritter Pharmaceuticals, Inc. Hires Dr. Howard Foyt as Exec VP, Development & Chief Medical Officer [84]